Geron (GERN) Stock Price & Analysis

GERN$0.97-0.03 -2.72%
BiotechnologyGrowth Stock
Compare
Market cap$622.98MEnterprise value$634.13MRevenue (TTM)$204.56MMarket position—

Score

66
Bullish
Value
59
Quality
44
Growth
96

AI Analysis

Snapshot

Geron is a growth-led story right now — Growth 96/100 is the pillar doing the heavy lifting (overall 66/100) in Biotechnology. Under the hood: revenue compounding ~10822% annually over recent years. Street targets still imply ~509% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

59
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

96
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

44
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Geron Corporation (GERN) last printed $0.97. Equity value is $622.98M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$6.16M$1.06M$1.07M$460,000.00$253,000.00$1.39M$596,000.00$237,000.00$76.99M$183.88M

About

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Geron (GERN) Stock Price & Analysis

GERN price $0.97 -0.03 -2.72%

Ticker
GERN
Price
$0.97
Change
-0.03 -2.72%
Market cap
$622.98M
Forward P/E
9.94
Dividend yield
0.00%
Beta
0.61
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
66
Value
59
Quality
44
Growth
96

Stocklytics score rationale: value 59, quality 44, growth 96.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener